Figure 5. dCAFs were related to prognosis and platinum response in OC. (A) KM survival analysis of CAF-based cancer subtypes. (B) The expression level of dCAF marker genes in dCAF-based cancer subtypes. (C) GSEA of GSE30161- and GSE63885-derived platinum resistance gene in dCAF-based cancer subtypes. Feature plot of these genes in stromal cells. (D) IC50 of drugs including cisplatin, paclitaxel, gemcitabine, gefitinib, doxorubicin, and etoposide in dCAF-based cancer subtypes, calculated by pRRophetic algorithm. (***p < 0.001, **p < 0.01, *p < 0.05).